RxDoctor Payments Data

Craig Kopecky, MD

Internal Medicine · Lakeway, TXNPI 1174756365

Payments from drug & device makers

$2,068in general payments, 2019–2025

Across 111 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$407
  • AbbVie$295
  • Abbott$236
  • Lilly USA, LLC$190
  • Novo Nordisk$190
  • Pfizer$121
  • plus $629 from 19 others

What the payments were for

  • Food & beverage$2,068100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,068 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$199,562
Medicare patients
388
Services billed
2,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide72$78,163
OzempicSemaglutide71$76,244
JardianceEmpagliflozin66$73,310
EliquisApixaban58$60,269
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$23,307
FarxigaDapagliflozin Propanediol12$19,331
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$6,751
Praluent PenAlirocumab14$6,562
VascepaIcosapent Ethyl12$6,095
PaxlovidNirmatrelvir/Ritonavir25$4,287
Rosuvastatin Calcium307$3,620
Arnuity ElliptaFluticasone Furoate13$3,379
Levothyroxine Sodium278$2,805
Atorvastatin Calcium321$2,771
SynthroidLevothyroxine Sodium46$2,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$190$78,16372 claims
Novo NordiskOzempic$190$76,24471 claims
Boehringer IngelheimJardiance$77$73,31066 claims
PfizerEliquis, Paxlovid$121$64,55683 claims
GSKTrelegy Ellipta, Arnuity Ellipta$407$26,68638 claims
AstraZenecaFarxiga$19$19,33112 claims
AbbVieSynthroid, Armour Thyroid$295$3,40257 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$56$2,805278 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lakeway

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →